Dissecting origin factors of lymph node metastasis in non-small cell lung cancer via multimodal omics.
2/5 보강
OpenAlex 토픽 ·
Lung Cancer Treatments and Mutations
Cancer Genomics and Diagnostics
Bioinformatics and Genomic Networks
Cancer metastasis accounts for the majority of cancer-related deaths and lymph node metastasis is critical in cancer staging and prognosis.
APA
Di CHEN, Yu Liu, et al. (2026). Dissecting origin factors of lymph node metastasis in non-small cell lung cancer via multimodal omics.. Nature communications. https://doi.org/10.1038/s41467-026-71819-9
MLA
Di CHEN, et al.. "Dissecting origin factors of lymph node metastasis in non-small cell lung cancer via multimodal omics.." Nature communications, 2026.
PMID
41975179 ↗
Abstract 한글 요약
Cancer metastasis accounts for the majority of cancer-related deaths and lymph node metastasis is critical in cancer staging and prognosis. However, the mechanisms involved in lymph node metastatic non-small cell lung cancer (NSCLC) remain unclear. Here, we delineate the cellular and spatial landscape of metastatic lymph nodes and their matched primary tumors in NSCLC using multimodal omics. In results, tumor core and peripheral regions respectively exhibit high stemness and elevated expression of immunoglobulins. Increased expressions of CD274 (PD-L1) are observed in the immunoglobulin-high malignant cells and SPP1+IFI30+ macrophages. Notably, residual and tertiary lymphoid structures are identified. However, their anti-tumor immunity is compromised by CXCL13+ T cell exhaustion and immune exclusion. Furthermore, we identify the ferroptosis signaling, with its key factor FTH1 showing strong associations with cancer cell stemness and metastasis. This study elucidates the mechanisms of metastasis and immune evasion in lymph node metastatic NSCLC, providing insights for targeted therapies.
같은 제1저자의 인용 많은 논문 (5)
- Formation of charge-polarized regions at dual single-atom sites for C-H bond activation in methane.
- Discovery of as a Potent, Orally Bioavailable, and Highly Selective CDK12/13 Dual Degrader for the Treatment of Triple-Negative Breast Cancer.
- Enhanced Immunotherapy for Glioblastoma Using a Cholesterol Oxidase-Loaded, Pd-Doped CuN Nanozyme-Based Multimodal Nanoplatform.
- Clinicopathological and Genomic Analysis of -Deficient Non-Small Cell Lung Cancer: A Retrospective Cohort Study.
- Rescue Radiosensitization of Pancreatic Cancer via PD-L1/TGF-β1 Dual-Blockade Nanotherapy as Evaluated in 3-Dimensional Microtumors.